Strata | Type of transition | Obesity (vs no obesity)1 | DM (vs no DM)1 | CVD (vs no CVD)1 |
---|---|---|---|---|
n (vs n) for transitions | ||||
aHR (95% CI) | ||||
Women | Development of rHOA | |||
No rHOA/symptoms (A) to rHOA (B) | 56 (vs 77) | 25 (vs 108) | 49 (vs 84) | |
0.85 (0.59, 1.21) | 1.03 (0.61, 1.75) | 1.42 (0.98, 2.05) | ||
Symptoms only (C) to sxHOA (D) | 28 (vs 21) | 13 (vs 36) | 32 (vs 17) | |
1.27 (0.73, 2.20) | 1.42 (0.74, 2.75) | 1.23 (0.70, 2.17) | ||
Development of symptoms | ||||
No rHOA/symptoms (A) to symptoms only (C) | 108 (vs 77) | 39 (vs 146) | 64 (vs 121) | |
1.44 (1.02, 2.02) | 0.92 (0.56, 1.50) | 1.22 (0.83, 1.79) | ||
rHOA (B) to sxHOA (D) | 55 (vs 59) | 26 (vs 88) | 51 (vs 63) | |
0.70 (0.43, 1.13) | 1.42 (0.78, 2.61) | 0.94 (0.58, 1.54) | ||
Resolution of symptoms | ||||
Symptoms only (C) to no rHOA/symptoms (A) | 122 (vs 86) | 48 (vs 160) | 75 (vs 133) | |
0.93 (0.68, 1.27) | 0.78 (0.49, 1.22) | 0.60 (0.42, 0.87) | ||
sxHOA (D) to rHOA (B) | 69 (vs 49) | 26 (vs 92) | 52 (vs 66) | |
0.71 (0.44, 1.13) | 0.86 (0.48, 1.54) | 0.60 (0.38, 0.94) | ||
Men | Development of rHOA | |||
No rHOA/symptoms (A) to rHOA (B) | 26 (vs 39) | 14 (vs 51) | 20 (vs 45) | |
0.93 (0.55, 1.57) | 1.10 (0.52, 2.31) | 1.08 (0.53, 2.19) | ||
Symptoms only (C) to sxHOA (D) | 10 (vs 6) | 5 (vs 11) | 9 (vs 7) | |
2.14 (0.88, 5.21) | 1.26 (0.46, 3.47) | 0.68 (0.21, 2.17) | ||
Development of symptoms | ||||
No rHOA/symptoms (A) to symptoms only (C) | 48 (vs 56) | 25 (vs 79) | 44 (vs 60) | |
1.15 (0.74, 1.79) | 1.32 (0.71, 2.45) | 1.26 (0.75, 2.13) | ||
rHOA (B) to sxHOA (D) | 32 (vs 26) | 13 (vs 45) | 20 (vs 38) | |
1.50 (0.78, 2.88) | 0.81 (0.33, 2.03) | 1.46 (0.65, 3.28) | ||
Resolution of symptoms | ||||
Symptoms only (C) to no rHOA/symptoms (A) | 42 (vs 51) | 19 (vs 74) | 32 (vs 61) | |
0.78 (0.49, 1.24) | 0.70 (0.38, 1.30) | 0.61 (0.36, 1.05) | ||
sxHOA (D) to rHOA (B) | 35 (vs 21) | 12 (vs 44) | 20 (vs 36) | |
1.15 (0.60, 2.21) | 0.28 (0.10, 0.81) | 1.12 (0.54, 2.33) |